Conference
Olaparib efficacy in patients with metastatic castration-resistant prostate cancer (mCRPC) carrying circulating tumor (ct) DNA alterations in BRCA1 , BRCA2 or ATM : Results from the PROfound study.
Abstract
27
Background: ctDNA testing offers additional opportunities for homologous recombination repair (HRR) gene alteration determination in patients who are not able to access tumor tissue testing. Alteration testing in ctDNA, for BRCA1, BRCA2 and ATM alterations was performed retrospectively in the PROfound study (phase 3 trial of olaparib versus physician’s choice of abiraterone or enzalutamide in men with HRR gene-mutated mCRPC …
Authors
Matsubara N; De Bono JS; Olmos D; Procopio G; Kawakami S; Urun Y; van Alphen RJ; Flechon A; Carducci MA; Choi YD
Volume
39
Pagination
pp. 27-27
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
February 20, 2021
DOI
10.1200/jco.2021.39.6_suppl.27
Conference proceedings
Journal of Clinical Oncology
Issue
6_suppl
ISSN
0732-183X